Looking At Eli Lilly’s Recent Unusual Options Activity
A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly.…
Nasdaq Futures Climb Solidly After Past Week’s Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis.
Wells Fargo Upgrades Eli Lilly to Overweight, Raises Price Target to $375
Wells Fargo analyst Mohit Bansal upgrades Eli Lilly (NYSE:LLY) from Equal-Weight to Overweight and raises the price target from $360 to $375.
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
U.S. FDA Broadens Indication For Verzenio In HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade, regardless of Ki-67 score
Approval supported by four-year data
Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $444
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $455 to $444.
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
Guggenheim Partners initiated coverage on Structure Therapeutics Inc (NASDAQ:GPCR) with a Buy rating and a price target of $50 based on the multi-billion-dollar…
$100 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 24.56% on an annualized basis…